GlassScriptPhysician profile
Mary M Scheyd
NPI 1144415605
$5,468.47
in general payments reported to CMS, 2019-2025
32 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $1,383 · 2023: $784 · 2024: $1,274 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,457.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $689.35 | 2021-2025 | Lifevest |
| Medtronic, INC. | $608.41 | 2021-2025 | Symplicity G3, Linq II |
| Boston Scientific Corporation | $488.08 | 2021-2025 | Resonate El Icd Vr, Watchman Access System, Watchman Flx |
| Kestra Medical Technology Services, INC. | $397.67 | 2022-2025 | Assure Wcd |
| Inspire Medical Systems, INC. | $313.80 | 2022-2025 | Inspire |
| Abbott Laboratories | $313.67 | 2021-2023 | Aveir, Jot Dx, Cardiomems |
| Janssen Pharmaceuticals, INC | $298.34 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $298.05 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $264.82 | 2024-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $229.43 | 2023-2024 | Farxiga, Andexxa |
| Novartis Pharmaceuticals Corporation | $202.74 | 2023-2024 | |
| Edwards Lifesciences Corporation | $143.83 | 2025 | |
| Philips North America LLC | $139.11 | 2023-2025 | (Ck4) Mcot, Ambulatory Monitoring & Diagnostics Undivided, (5044) Mcot |
| Merck Sharp & Dohme LLC | $124.88 | 2023-2025 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.30 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $104.72 | 2022 | |
| Bard Peripheral Vascular, INC. | $101.52 | 2022 | |
| Neurelis, INC. | $101.00 | 2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $85.29 | 2021 | |
| Abiomed | $60.75 | 2024-2025 | Impella |
| Pfizer INC. | $58.11 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $56.01 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.37 | 2024-2025 | Jardiance |
| Amgen INC. | $41.45 | 2021-2023 | Repatha |
| Esperion Therapeutics, INC. | $40.18 | 2021-2024 | Nexletol |
| Cvrx, INC. | $28.93 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $27.50 | 2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $22.38 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $19.87 | 2025 | Uptravi |
| Convatec INC. | $19.71 | 2022 | |
| Cardiva Medical, INC. | $19.59 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Bayer Healthcare Pharmaceuticals INC. | $15.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Scheyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.